A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

Trial Profile

A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Taselisib (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms Lung-MAP Sub-Study
  • Most Recent Events

    • 02 Jun 2017 The initial protocol randomized PIK3 mt (+) pts to taselisib 4 mg po daily or docetaxel, but was amended to single arm phase II trial of taselisib.
    • 02 Jun 2017 Status changed from active, no longer recruiting to discontinued, according to an abstract presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Primary endpoint [ Objective Response Rate (ORR) (confirmed and unconfirmed, complete and partial) (Design #2, Phase II))] has not been met, according to the interim results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top